Truist Financial Corp Purchases 272 Shares of argenx SE (NASDAQ:ARGX)

Truist Financial Corp increased its stake in shares of argenx SE (NASDAQ:ARGX) by 6.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,283 shares of the company’s stock after acquiring an additional 272 shares during the quarter. Truist Financial Corp’s holdings in argenx were worth $2,634,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Nkcfo LLC bought a new stake in shares of argenx in the 4th quarter worth approximately $68,000. Advisors Preferred LLC purchased a new position in argenx during the fourth quarter valued at $73,000. GAMMA Investing LLC raised its stake in argenx by 44.8% during the fourth quarter. GAMMA Investing LLC now owns 252 shares of the company’s stock valued at $155,000 after buying an additional 78 shares during the last quarter. Keudell Morrison Wealth Management purchased a new position in argenx during the third quarter valued at $207,000. Finally, SG Americas Securities LLC raised its stake in argenx by 6.2% during the fourth quarter. SG Americas Securities LLC now owns 358 shares of the company’s stock valued at $220,000 after buying an additional 21 shares during the last quarter. 60.32% of the stock is currently owned by institutional investors.

argenx Stock Down 0.2 %

Shares of argenx stock opened at $624.94 on Wednesday. argenx SE has a twelve month low of $349.86 and a twelve month high of $678.21. The business has a 50-day moving average price of $642.66 and a 200 day moving average price of $589.24. The firm has a market cap of $37.97 billion, a PE ratio of -710.16 and a beta of 0.58.

Analyst Ratings Changes

ARGX has been the subject of a number of research analyst reports. Guggenheim lifted their target price on argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Scotiabank raised argenx from a “sector perform” rating to a “sector outperform” rating and boosted their price target for the company from $439.00 to $715.00 in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft lowered argenx from a “hold” rating to a “sell” rating in a report on Friday, January 17th. Wells Fargo & Company boosted their price objective on argenx from $639.00 to $723.00 and gave the company an “overweight” rating in a research report on Thursday, December 19th. Finally, Baird R W downgraded argenx from a “strong-buy” rating to a “hold” rating in a research report on Friday, November 1st. One analyst has rated the stock with a sell rating, two have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, argenx currently has a consensus rating of “Moderate Buy” and an average target price of $658.39.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.